Loading…

Lilly (Eli)LLYCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Develops branded medicines including diabetes/obesity drugs (Mounjaro, Zepbound), oncology and immunology treatments.

Momentum leader 88
Mkt cap
$1.30T
US dollars, full cap
Free float
90%
of shares outstanding
$/day
$4.27B
20-day average traded
Fwd P/E
29.5×
forward earnings
ROIC−WACC
+34.2 pp
WACC 7.0%
Hurdle
-15 pp
Req g minus delivered
Official | Implied
AA- / AA+
agencies · bond market
Next earnings
84 days
10 Feb 2027
Close · USD$1,383
1D-2.3%
1W-3.8%
1M+7.7%
3M+11.1%
6M+35.7%
YTD+29.1%
1Y+35.8%
ATR %3.1%
Beta0.33
52w lowhigh6.3% off high

What Lilly (Eli) does

Develops branded medicines including diabetes/obesity drugs (Mounjaro, Zepbound), oncology and immunology treatments.

Earns from patented medicines sold through insurers and pharmacy benefit managers, who negotiate price and coverage. The tirzepatide drugs for diabetes and obesity have become the largest part, so supply is the limit and it has been building new factories in the US and abroad.

Products and services

  • Mounjaro/Zepbound (tirzepatide)
  • Trulicity
  • Verzenio (oncology)
  • Taltz (immunology)

Customers

  • Physicians/health systems
  • Payers/PBMs
  • Patients

Where it sits in the supply chain

  • Pharmaceuticals
  • Branded biopharma
  • Diabetes/obesity, oncology, immunology

What could go right

  • GLP-1 obesity/diabetes demand growth
  • Pipeline expansion into new indications

What could go wrong

  • GLP-1 manufacturing capacity constraints
  • Compounded/generic GLP-1 competition, patent cliffs

Moat: wide (IP / patents, scale, brand). Patent-protected GLP-1 franchise with manufacturing scale that rivals cannot match near-term.

Headquarters: Indianapolis, Indiana, United States · Founded: 1876 · Employees: 50,000

Named competitors

Lilly (Eli) at a glance

Size Lilly (Eli) (LLY) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.30T, the 11th largest of 3,085 United States companies the cockpit tracks. Shares closed at $1,383 on 18 Nov 2026.

Performance Over six months the shares gained 35.7%, against +17.5% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.

Growth Revenue grew 45.5% over the last twelve months (peer median +6.0%); the operating margin is 51.2% (peer median 26.6%).

Valuation It trades at 29.5× forward earnings against a peer median of 17.5× (4th most expensive of 21).

Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +22%, so the hurdle is -15 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 34.2 points above its cost of capital (7.0% WACC).

Credit Lilly (Eli) has 53 bonds outstanding ($49.0B), rated AA- by the agencies and trading like AA+ at a weighted spread of 57 bp.

Short interest Short interest is 0.8% of the free float (30 Oct 2026).

Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026LLY 133Peer median 115
Six months, rebased to 100: Lilly (Eli) against the median of its 20 peers (local-currency closes).

Lilly (Eli) financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$86.5B$65.2B$45.0B$34.1B$28.5B
Revenue growth—+45%+32%+20%—
Gross profit$72.3B$54.1B$36.6B$27.0B$21.9B
EBITDA$46.5B$31.7B$18.8B$11.9B$9.80B
Net income$27.6B$20.6B$10.6B$5.24B$6.24B
Free cash flow$19.7B$8.97B$3.76B$792M$5.23B
Capital expenditure$19.0B$10.8B$8.40B$7.39B$2.48B
Total debt$49.5B$43.9B$33.6B$25.2B$16.2B

Quarterly statements and history in the cockpit →

Lilly (Eli) competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%0%+10%JNJABBVROMRKNOVNAZNNOVO-BPFEBMYSANGSKREGN4519MRK4502603259BAYNGALDSUNPHARMALLY6-month return →1-month return →
Up and to the right = strong over both horizons. Lilly (Eli) is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%+40%20×40×JNJABBVROMRKNOVNAZNNOVO-BPFEVRTXBMYSANREGN4519MRK4502603259BAYNGALDSUNPHARMALLYRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Lilly (Eli) is the large dot.

Capital: growth delivered against growth the price implies

-10%0%+10%+20%+30%0%20%JNJABBVROMRKNOVNAZNNOVO-BPFEVRTXBMYSANGSKREGN4519MRK603259GALDSUNPHARMALLYGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Lilly (Eli) is the large dot.

Lilly (Eli) competitors and peer comparison

Head to head with its named competitors (LLY vs NOVO-B.CO vs PFE vs MRK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Lilly (Eli) LLY$1.30T+36%+46%51%29.5×6.5%
Novo Nordisk A/S NOVO-B.CO$177B-6%+6%48%11.8×-0.5%
Pfizer PFE$160B+9%+1%26%9.9×-4.3%
Merck & MRK$340B+23%+5%18%16.4×8.3%
AbbVie ABBV$506B+35%+11%36%18.1×-0.1%

How Lilly (Eli) compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Lilly (Eli) against its 20 peers (data as of 18 Nov 2026)
MeasureLLYPeer medianRank in peer set
1-month return+7.7%+4.1%7th highest of 21
6-month return+35.7%+17.5%4th highest of 21
Distance from 52-week high-6.3%-5.9%10th lowest of 21
Revenue growth (TTM)+45.5%+6.0%highest of 21
Operating margin51.2%26.6%highest of 21
Forward P/E29.5×17.5×4th most expensive of 21
Growth the price implies (Req g, 7 yrs)6.5%3.7%7th most demanding of 20
Growth delivered (Del g)+21.6%+7.1%2nd highest of 20
Hurdle (Req g minus delivered)-15.0 pp-3.4 pp4th least demanding of 20
ROIC minus cost of capital+34.2 pp+8.1 pphighest of 21
EV / EBITDA28.9×14.9×2nd most expensive of 20
Net debt / EBITDA1.0×1.2×8th least indebted of 20
Bond spread57 bp69 bp4th tightest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Lilly (Eli) LLYUnited States$1.30T+36%+46%51%29.5×6.5%+21.6%
Johnson & Johnson JNJUnited States$656B+20%+8%26%24.2×3.7%+2.7%
AbbVie ABBVUnited States$506B+35%+11%36%18.1×-0.1%+6.0%
Roche RO.SWSwitzerland$381B+21%-1%31%19.9×1.7%+1.1%
Merck & MRKUnited States$340B+23%+5%18%16.4×8.3%+9.3%
Novartis NOVN.SWSwitzerland$285B+11%-4%30%17.5×1.6%-0.2%
AstraZeneca AZN.LUnited Kingdom$278B-2%+5%23%17.6×14.4%+15.7%
Novo Nordisk A/S NOVO-B.CODenmark$177B-6%+6%48%11.8×-0.5%+19.5%
Pfizer PFEUnited States$160B+9%+1%26%9.9×-4.3%+8.5%
Vertex Pharmaceuticals VRTXUnited States$136B+25%+11%35%28.5×6.2%+14.2%
Bristol Myers Squibb BMYUnited States$122B+3%+4%33%9.2×-13.1%+2.5%
Sanofi SAN.PAFrance$114B+13%+15%27%9.7×-4.8%+3.9%
GSK GSK.LUnited Kingdom$97.9B-3%+4%25%10.4×-0.1%-0.9%
Regeneron Pharmaceuticals REGNUnited States$97.8B+46%+19%30%11.8×-1.1%+11.0%
Chugai Pharmaceutical 4519.TJapan$75.2B-8%+17%50%23.7×5.0%+9.8%
Merck KGaA MRK.DEGermany$71.3B+16%+1%19%17.4×7.4%+3.8%
Takeda Pharmaceutical 4502.TJapan$69.8B+30%+6%18%51.0×3.7%+7.1%
WuXi AppTec 603259.SSChina$64.2B+40%+32%43%17.0×7.2%+22.3%
Bayer BAYN.DEGermany$60.3B+48%0%13%12.3×n/an/a
Galderma GALD.SWSwitzerland$51.9B+18%+16%19%45.7×18.0%+6.4%
Sun Pharmaceutical Industries SUNPHARMA.NSIndia$48.0B-1%+12%23%36.0×28.7%+11.7%

Lilly (Eli) bonds and credit

Lilly (Eli) has 53 bonds outstanding with $49.0B face value. The agencies rate it AA-; its bonds trade like AA+. Weighted yield 5.31%, a spread of 57 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Lilly (Eli)'s main competitors?
Named competitors: Novo Nordisk (NOVO-B.CO), Pfizer (PFE), Merck (MRK), AbbVie (ABBV). The cockpit's measured peer set (industry) also includes Johnson & Johnson (JNJ), AbbVie (ABBV), Roche (RO.SW), Merck & (MRK), Novartis (NOVN.SW), AstraZeneca (AZN.L).
Is Lilly (Eli) expensive compared with its peers?
On forward p/e it trades at 29.5× against a peer median of 17.5×, 4th most expensive of 21 in its peer set. For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +22%, so the hurdle is -15 pp: the price already allows for a slowdown.
How has Lilly (Eli) stock performed?
Over six months to 18 Nov 2026 the shares returned +35.7% against +17.5% for the median peer; over one year +35.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.